8 drug(s) with this reaction
2,917 total reports
Oedema Peripheral has been reported as an adverse reaction across 8 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 2,917 adverse event reports mention oedema peripheral in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with oedema peripheral, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have oedema peripheral listed in their FDA adverse event reports, sorted by report count:
In addition to oedema peripheral, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
8 drug(s) manufactured by Amgen Inc have oedema peripheral listed in their FDA adverse event reports: DENOSUMAB, DARBEPOETIN ALFA, FILGRASTIM, EPOETIN ALFA, IVABRADINE, and others.
There are a combined 2,917 reports of oedema peripheral across 8 Amgen Inc drug(s) in the FDA adverse event database.